CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Awards (Tables)

Equity Awards (Tables)

3 Months Ended

Aug. 31, 2022

Equity Awards

Schedule of Warrant Liability and Equity


(in thousands)		Liability Classified Warrants
Balance at May 31, 2022	$	—
Classified as liability due to lack of shares availability at issuance		14,522
Classified as equity upon increase in availability		(23,123)
Loss on derivative due to change in fair market value		8,601
Balance at August 31, 2022	$	—

Stock Option and Warrant Activity


							Weighted
							average
				Weighted			remaining		Aggregate
		Number of		average			contractual		intrinsic
(in thousands, except per share data)		shares		exercise price			life in years		value
Options and warrants outstanding at May 31, 2022		90,705		$	0.77		4.06		$	352
Granted		104,104		$	0.25
Exercised		(863)		$	0.49
Forfeited, expired, and cancelled		(484)		$	1.57
Options and warrants outstanding at August 31, 2022		193,462		$	0.48		4.36		$	36,758
Options and warrants outstanding and exercisable at August 31, 2022		187,896		$	0.45		4.24		$	36,717